The first-generation CAR molecules, with only an scFv against a cell surface antigen expressed on tumour cells and the cytoplasmic CD3 zeta chain signalling domain, were found to have limited clinical activity for the treatment of lymphoma 47, neuroblastoma 57, ovarian cancer 60 and renal cancer 46. The gene discussed is CD53; the disease is neoplasm.